How to cure an ailing antibiotics business? | FT Rethink

Financial Times3 hours ago2:53

Developing new antibiotics can be a long and costly process with no guarantee of profit. While many pharma companies have dropped out of the business, the FT’s Aanu Adeoye explores how others are finding ways to bring new, desperately needed drugs to market. ► Enjoying FT content? Get a daily slice of the very best FT journalism with FT Edit. Free for 30 days then just £4.99 a month See if you get the FT for free as a student (http://ft.com/schoolsarefree) or start a £1 trial: https://subs.ft.com/spa3_trial?segmentId=3d4ba81b-96bb-cef0-9ece-29efd6ef2132. ► Check out our Community tab for more stories: https://www.youtube.com/@FinancialTimes/community ► Listen to our podcasts: https://www.ft.com/podcasts ► Follow us on Instagram: https://www.instagram.com/financialtimes ► Follow us on Instagram: https://www.tiktok.com/@financialtimes

How to cure an ailing antibiotics business? | FT Rethink | PiQ Markets